Andrew G Sikora
Affiliation: Mount Sinai School of Medicine
- A patient-centered approach to counseling patients with head and neck cancer undergoing human papillomavirus testing: a clinician's guideAmy Chu
Department of Otolaryngology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, Box 1189, New York, New York 10029, USA
Oncologist 18:180-9. 2013..Based on the current state of the literature, this article is intended to be a reference for physicians to effectively manage psychosocial outcomes when diagnosing patients with HPV-associated OPC...
- Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapyAndrew G Sikora
Department of Melanoma Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Clin Cancer Res 16:1834-44. 2010..We tested the hypothesis that targeted iNOS inhibition would interfere with human melanoma growth and survival in vivo in a preclinical model...
- Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor releasePadmini Jayaraman
Department of Otolaryngology, Mount Sinai School of Medicine, New York, NY 10028, USA
J Immunol 188:5365-76. 2012..These data suggest a critical role for tumor-expressed iNOS in the recruitment and induction of functional MDSC by modulation of tumor VEGF secretion and upregulation of STAT3 and ROS in MDSC...
- Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancerCharles C L Tong
Department of Otolaryngology, Head and Neck Surgery, The Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1189, New York, NY, USA
Immunol Res 54:266-74. 2012..This article outlines significant immune-suppressive mechanisms in the HNSCC tumor microenvironment and potential approaches to enhancing the antitumor immune response...
- IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activityAndrew G Sikora
Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
J Immunol 182:7398-407. 2009....
- Prognostic significance of p16 in locoregionally advanced head and neck cancer treated with concurrent 5-fluorouracil, hydroxyurea, cetuximab and intensity-modulated radiation therapyCharles C L Tong
Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
Oncol Rep 27:1580-6. 2012..The most common grade 3-4 toxicities were mucositis (46%), leukopenia (18%), anemia (18%) and dermatitis (17%). Concurrent 5-FU, HU, cetuximab and SIB-IMRT is a highly active regimen, particularly in patients with p16-positive disease...
- Conference scene: immune effector mechanisms in tumor immunityAndrew G Sikora
Departments of Otolaryngology, Immunology, Oncological Sciences and Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA
Immunotherapy 4:141-3. 2012..The conference built on these early successes and aimed to push further into the uncharted territories of successful cancer immunotherapy...
- Predictors of survival in mucosal melanoma of the head and neckDaniel Jethanamest
Department of Otolaryngology Head and Neck Surgery, New York University School of Medicine, New York, NY, USA
Ann Surg Oncol 18:2748-56. 2011..In order to identify factors predictive of survival, we analyzed MMHN outcomes in a large US cohort...
- Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in miceChengwen Liu
Department of Melanoma Medical Oncology, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
J Clin Invest 118:1165-75. 2008..Our data thus demonstrated that activated pDCs are capable of initiating effective and systemic antitumor immunity through the orchestration of an immune cascade involving the sequential activation of NK cells, cDCs, and CD8(+) T cells...